There is no question that CGM is truly groundbreaking technology. We have written extensively on this subject noting not just how CGM will become the standard for glucose measurement but how when this data is acted upon it can lead to improvement in patient outcomes. Nothing new here. We have also noted that this market is not just growing but has room for multiple players. Again, no news here.
So, we were a little surprised that the American Association of Clinical Endocrinologists felt it necessary to come up with IDEA. IDEA stands for Innovating Decisions and Empowering Action in Diabetes . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.